1. Background {#sec1}
=============

Previous studies of prostate cancer have shown elevated rates in agricultural and pesticide manufacturing populations \[[@B1], [@B2]\]. In the Agricultural Health Study (AHS), a significant excess of prostate cancer was observed among private and commercial pesticide applicators compared to the general population \[[@B3], [@B4]\]. Also, use of pesticides, such as phorate \[[@B5]\], fonofos \[[@B6]\], butylate \[[@B7]\], and coumaphos \[[@B8]\], has been linked with an increased risk of prostate cancer among AHS participants with a family history of prostate cancer. We conducted a prostate cancer nested case-control study within the AHS to examine interactions between prespecified genetic pathways and pesticide exposure. Recent findings from this study have identified significant pesticide interactions for several genetic variants in the 8q24 region \[[@B9]\], xenobiotic metabolism pathway \[[@B10]\], and DNA repair pathways \[[@B11], [@B12]\]. These studies help elucidate exposure-effect associations by identifying potentially susceptible subgroups. This allows us to better understand potential carcinogenic hazards and furthers public health research on the human health effects of pesticides.

In this analysis, we evaluated single nucleotide polymorphisms (SNPs) in genes related to lipid metabolism since there is evidence that lipogenic enzymes and serum lipids may play a role in prostate carcinogenesis via inflammatory, oxidative stress and insulin-resistance mechanisms \[[@B13], [@B14]\]. Cellular and molecular studies have reported an overexpression of lipogenic enzymes, such as fatty acid synthase and acetyl-CoA carboxylase, and increased lipogenesis in prostate cancer cells \[[@B15], [@B16]\]. Genetic variants involved in fatty acid or lipid metabolism, which have been linked to altered expression of lipogenic enzymes and serum lipid levels \[[@B16]--[@B18]\], have also been associated with an excess risk of prostate cancer \[[@B19]--[@B21]\]. Furthermore, several pesticides are lipophilic or are metabolized via a lipid-related mechanism \[[@B22], [@B23]\], suggesting that variants of genes involved in lipid metabolism may interact with certain pesticides to increase the risk of prostate cancer. We examined potential gene-environment interactions between SNPs in genes involved in lipid metabolism and pesticide exposure in a nested case-control study within the AHS.

2. Methods {#sec2}
==========

2.1. Study Subjects {#sec2.1}
-------------------

A detailed description of the AHS cohort has been published \[[@B24]\]. Briefly, 57, 310, or 82%, of pesticide applicators seeking pesticide licensing in Iowa and North Carolina were enrolled in the study between December 13, 1993 and December 31, 1997. Participants were licensed private pesticide applicators (mostly farmers) residing in Iowa and North Carolina and commercial applicators residing in Iowa. To be eligible for this nested case-control study, participants had to provide a mouth-wash rinse buccal cell sample, and could not have had a previous cancer diagnosis except for non-melanoma skin cancer. Cancer diagnoses were identified by linkage with population-based state cancer registries. Cases were males diagnosed with incident prostate cancer between 1993 and 2004, and controls were males alive at the time of case diagnosis with no cancer diagnosis, except nonmelanoma skin cancer at the time of selection. Eligible controls were randomly selected and frequency matched 2 : 1 to cases by date of birth (±1 year). All participants were self-identified as Caucasian and confirmed to be of European ancestry using population substructure evaluation and principal component analysis as previously described \[[@B9]\].

2.2. Pesticide Use {#sec2.2}
------------------

Information on pesticide use was obtained from two self-administered questionnaires completed at enrollment (<http://aghealth.nci.nih.gov/questionnaires.html>). These questionnaires collected comprehensive data on lifetime use of 50 pesticides. Participants were asked how many years (1 year or less, 2--5, 6--10, 11--20, 21--30, or more than 30 years) and how many days (less than 5, 5--9, 10--19, 20--39, 40--59, 60--150, or more than 150 days) in an average year they applied each chemical. Pesticide use was quantified as ever/never use, lifetime exposure days (years of use × days per year), and intensity weighted lifetime exposure days (lifetime exposure days × intensity score). The intensity score was computed from an algorithm that took into account exposure-modifying factors of how pesticides were used and applied \[[@B25]\].

2.3. SNP Selection and Genotyping {#sec2.3}
---------------------------------

Germline DNA was extracted from buccal cells using Autopure (QIAGEN) at Sera Care, Frederick, MD. Genotyping was conducted with a custom Infinium BeadChip Assays (iSelect)from Illumina Inc., at the NCI Core Genotyping Facility (<http://cgf.nci.nih.gov/operations/multiplex-genotyping.html>). Common SNPs (minor allele frequency ≥ 5%) with an *r*^2^ threshold \>0.80 were selected from the HapMap Project population using the Tagzilla software package that implements a modified tag SNP selection method described by Carlson et al. \[[@B26]\]. The Illumina chip included 26, 512 SNPs, of which 1,858 tag SNPs in 85 genes were related to the lipid metabolism pathway. Blinded duplicate samples (2%) were genotyped; the concordance of these samples ranged from 96--100%. The overall genotyping rate for lipid metabolism SNPs was between 97% and 100%. Of the samples genotyped, 108 were removed due to insufficient or poor DNA quality (14 cases, 6 controls) or \<90% completion rate (47 cases, 41 controls), leaving 2,220 (776 cases, 1,444 controls) for statistical analyses.

2.4. Statistical Analysis {#sec2.4}
-------------------------

We compared the distributions of selected characteristics (age (\<40, 40--49, 50--59, 60--69, ≥70), state of residence (Iowa, North Carolina), applicator type (private, commercial), and first-degree family history of prostate cancer (no, yes)) between cases and controls using a chi-square test.

Associations between the 1,895 lipid metabolism SNPs in 85 genes and prostate cancer risk were assessed using PLINK software \[[@B27]\] using a log-additive genetic model to calculate odd ratios (OR) and 95% confidence intervals (CI). Variants with a Hardy Weinberg equilibrium *P* value \>0.001, a minor allele frequency ≥0.1, and a *P* trend for the additive effect of each allele \<0.2 were carried forward for interaction analyses, which totaled 220 SNPs in 59 genes. Pairwise linkage disequilibrium (e.g., *D*′ and *r*^2^) between SNPs was evaluated using Haploview 4.2 \[[@B28]\].

The statistical interactions between pesticide use and genetic variants were assessed using the likelihood ratio test in unconditional logistic regression models adjusting for age and state. We examined 39 pesticides that were ever used by at least 10% of the study population. Exposure for each pesticide was categorized as nonexposed, low, and high exposure, with low- and high-exposure categories based on the median intensity-weighted lifetime days. Genetic variants were coded using a dominant genetic model due to the potential for small sample sizes of variant alleles. We calculated ORs and 95% CIs for prostate cancer risk and pesticide exposure stratified by genotype (homozygous wild-type, heterozygous and homozygous variant) using unconditional logistic regression models adjusting for age and state. In essence, we adopted a two-stage interaction approach \[[@B29]\], where we first set a cut point on the SNPs we included in the interaction analyses, and then cut point on the *P* interaction value to increase statistical power.

We used the false discovery rate (FDR) \[[@B30]\] to account for multiple comparisons for the main effect associations and the interactions. For the main effect associations, FDR was calculated considering all SNPs within each gene. For the interaction analyses, we calculated FDR in two ways: (1) accounting for the 220 SNPs we evaluated per pesticide, which is the most stringent approach, and (2) accounting for the number of SNPs within each gene per pesticide. Since our *a priori* hypothesis was an increased risk of cancer with exposure, we focused on statistically significant monotonically increasing ORs with increasing pesticide exposure in one genotype and no significant association in the other genotype (quantitative interaction), versus an interaction with increasing pesticide exposure in one genotype and a decreasing pesticide exposure in the other genotype (qualitative interaction), since the former are considered to be more biologically plausible and less due to chance \[[@B31]\]. Unless otherwise indicated, analyses were conducted using SAS, version 9.1 (SAS Institute, Cary, NC) and AHS data release version P1REL0712.04.

3. Results {#sec3}
==========

Characteristics of the study population (see Supplementary Table 1 in Supplementary Material available online at doi:10.1155/2012/358076) and associations between intensity-weighted lifetime days of pesticide use and prostate cancer (Supplementary Table 2) were previously published \[[@B9]--[@B12]\]. Briefly, cases and controls were similar in terms of age, state of residence and applicator type, but cases were more apt to have a family history of prostate cancer.

Of the 1,895 lipid metabolism SNPs in 85 genes we examined, 20 SNPs in 8 genes (*ABCG5*, *ALOXE3*, *AMACR*, *FOXA3*, *LRP2*, *PPARA*, *TBXAS1*, *UCP3*) were significant using a gene-based FDR \<0.05 ([Table 1](#tab1){ref-type="table"}). The two most significant SNP-cancer associations were for two highly correlated variants in *ABCG5,* rs1835815, and rs2278356 (*r*^2^ = 0.89, FDR *P* main effect = 0.01).

Among the 220 SNPs in 59 genes and 39 pesticides examined in interaction analyses, we found 16 interactions significant at FDR *P* interaction \<0.2 accounting for all 220 SNPs per pesticide. All of these interactions had a significant association between pesticide use and prostate cancer in at least one genotype group (*P* trend \< 0.05), 9 also had an increased risk of prostate cancer (OR trend \> 1.0); and three were monotonic associations (i.e., increasing cancer risk with increasing pesticide use) and quantitative interactions ([Table 2](#tab2){ref-type="table"}). These associations involved one pesticide, terbufos, and three SNPs in three genes (*ADIPOR1*, *ALOXE3*, *SEC14L2*).

Using a less stringent method for accounting for multiple comparisons, we found 139 interactions significant using a gene-based FDR for each of the 39 pesticides examined (FDR *P* interaction \< 0.05). Of these, 116 had significant associations between pesticide use and prostate cancer in at least one genotype group (*P* trend \< 0.05); 31 resulted in increased prostate cancer risk (OR trend \> 1.0) (Supplemental Table 4), and 17 were monotonic associations and quantitative interactions ([Table 3](#tab3){ref-type="table"}). These 17 associations involved seven pesticides (atrazine, carbofuran, EPTC, fonofos, glyphosate, petroleum oil/distillate, and terbufos) and 15 SNPs in 11 genes (*ABCG8*, *ACSL5*, *ADIPOR1*, *ALOX5*, *ALOX5AP*, *ALOX15*, *ALOXE3*, *A4GALT*, *LDLR*, *LRP1*, *SEC14L2*). The findings from this method are inclusive of those using the more stringent method.

We observed significant interactions with three insecticides, terbufos, fonofos, and carbofuran. Overall, the most noteworthy association (i.e., smallest FDR *P*-interaction and pesticide *P*-trend) was for terbufos and *ALOXE3*rs3027208 ([Table 3](#tab3){ref-type="table"}). Men carrying the variant T allele who were low users of terbufos had an OR of 1.86 (95%  CI = 1.16--2.99) and high users an OR of 2.00 (95%  CI = 1.28--3.15) compared to no use of terbufos (*P* trend = 0.001), while men carrying the CC genotype did not exhibit a significant association (FDR *P* interaction = 0.01). This association persisted after adjusting for *ALOXE3* rs6503086, which had a significant main effect association with prostate cancer (FDR *P* trend = 0.02) but was not correlated with rs3027208 (*r*^2^ = 0.02). Terbufos also interacted significantly with *SEC14L2* rs2072159 (FDR *P* interaction = 0.01) and *ADIPOR1* rs12733285 (FDR *P*-interaction = 0.02). Fonofos interacted significantly with *ABCG8* rs4953028, such that men carrying the GG genotype who were low users of fonofos had an OR of 1.73 (95% CI = 0.99--3.00) and high users an OR of 1.94 (95% CI = 1.17--3.20) compared to no use of fonofos (*P* trend = 0.004), while men carrying the variant A allele did not exhibit a significant association (FDR *P* interaction = 0.02). Carbofuran interacted significantly with *A4GALT* rs8136914 (FDR *P* interaction = 0.03) and with *LDLR* rs8110695 (FDR *P* interaction = 0.04).

We observed significant interactions with four herbicides, EPTC, petroleum oil/distillates, glyphosate, and atrazine. Among these, the most noteworthy association (i.e., smallest FDR *P* interaction and pesticide *P* trend) was for EPTC and *ALOX15* rs916055. Men carrying the G allele who were low users of EPTC had an OR of 1.47 (95% CI = 0.98--2.22) and high users an OR of 1.63 (95% CI = 1.06--2.50) compared to no use of EPTC (*P* trend = 0.01), while men carrying the A allele did not exhibit a significant association (FDR *P* interaction = 0.01). Petroleum oil interacted with variants in three genes (*ALOX5*, *LRP1*, and *ACSL5*). The most significant interaction for petroleum oil was with *ALOX5* rs7099684, such that men carrying the TT genotype who were low users of petroleum oil had an OR of 1.19 (95% CI = 0.76--1.86) and high users an OR of 1.56 (95% CI = 1.03--2.38) compared to no use of petroleum oil (*P* trend = 0.03), while men carrying the A allele did not exhibit a significant association (FDR *P*-interaction = 0.02). Petroleum oil interacted with four*LRP1* SNPs (rs1800159, rs6581128, rs795957, rs7978567) that are moderately to highly correlated (*r*^2^ = 0.56--0.88). The most significant association (i.e., smallest FDR *P*-interaction and *P*-trend) was for *LRP1*rs1800159, such that men carrying the A allele who were low users of petroleum oil had an OR of 1.26 (95% CI = 0.80--2.00) and high users an OR of 1.76 (95% CI = 1.12--2.77) compared to no use of petroleum oil (*P* trend = 0.01), while men carrying the G allele did not exhibit a significant association (FDR *P* interaction = 0.03). Petroleum oil also interacted significantly with two *ACSL5* SNPs (rs876873, rs120985760) that are highly correlated (*r*^2^ = 0.89). Other noteworthy associations included the interactions between glyphosate and *ALOX5AP* rs9579645 (FDR *P* interaction = 0.02), and between atrazine and *LDLR* rs8110695 (FDR *P* interaction = 0.03) as well as *LRP1* rs1800159 (FDR *P*-interaction = 0.04), which, as mentioned above, also interacted with petroleum oil.

4. Discussion {#sec4}
=============

In this nested case-control study, we evaluated the interaction between pesticide use and SNPs in genes related to lipid metabolism. We found 17 interactions that were robust to multiple comparison adjustment and displayed a significant monotonic increase in prostate cancer risk with increasing pesticide use in one genotype group and no significant association in the other genotype group. With these criteria, our analyses yielded seven pesticides (atrazine, carbofuran, EPTC, fonofos, glyphosate, petroleum oil/distillate, and terbufos) and 15 SNPs in 11 genes (*ABCG8*, *ACSL5*, *ADIPOR1*, *ALOX5*, *ALOX5AP*, *ALOX15*, *ALOXE3*, *A4GALT*, *LDLR*, *LRP1*, *SEC14L2*) of primary interest.

Increased prostate cancer risk has been associated with the insecticides (terbufos, fonofos, carbofuran) that we found to interact with lipid metabolism genes in previous studies in the AHS. Terbufos was suggestively linked to prostate cancer \[[@B32]\], but significantly with aggressive prostate cancer \[[@B4]\], and showed evidence of interaction with variants in the 8q24 region \[[@B9]\] and xenobiotic metabolism genes \[[@B10]\]. Fonofos has been linked to prostate cancer \[[@B3], [@B6]\] and aggressive prostate cancer \[[@B4]\], and interacted significantly with variants in the 8q24 region, and the nucleotide and base excision repair genes \[[@B11], [@B12]\]. Similarly, carbofuran has been linked to prostate cancer \[[@B3]\], and interacted with variants in the nucleotide excision repair pathway \[[@B12]\]. In contrast to the insecticides, none of the four herbicides we identified have been associated with prostate cancer risk in main effect studies in the AHS (petroleum oil \[[@B3], [@B4]\], EPTC \[[@B3], [@B4], [@B33]\], atrazine \[[@B34], [@B35]\], glyphosate \[[@B36]\]). However, in previous analyses in the prostate nested case-control study, petroleum oil interacted with xenobiotic metabolism genes \[[@B10]\].

Our findings support the hypothesis that genetic variation in lipid metabolism genes might modify the associations between pesticides and prostate cancer; however, the biologic mechanisms are unclear. Organochlorines are lipophilic and accumulate in animal and human adipose tissue \[[@B37], [@B38]\]; however, none of the six organochlorines we evaluated interacted significantly with the SNPs we examined. This may be due to organochlorines being of the market for approximately 30 years and having a very small number of participants who were exposed to these pesticides. Some pesticides in other classes have lipophilic properties or are metabolized via lipid-related mechanisms \[[@B37], [@B38]\]. For example, organosphosphates have been shown to inhibit triglycerides and lipoprotein lipases in laboratory mice \[[@B22], [@B39], [@B40]\]. Two (terbufos and fonofos) of the nine organophophates we examined interacted significantly with lipid metabolism gene variants and were associated with an increased risk of prostate cancer. Terbufos interacted with a variant in *ALOXE3*(arachidonate lipoxygenase 3), which is involved in a lipoxygenase reaction of a fatty acid that is converted to a molecule involved in the proliferation and specialization of the lipid membrane of the epidermis \[[@B41]\]. Terbufos also interacted with *ADIPOR1* (adiponectin receptor 1) that encodes the adiponectin receptor and mediates ligand activities, fatty acid oxidation, and glucose uptake by adiponectin \[[@B42]\]; and *SEC14L2* (SEC14-like protein 2) that is involved in lipid-binding and cholesterol biosynthesis \[[@B43]\]. Fonofos interacted with a variant in *ABCG8* (ATP-binding cassette, sub-family G member 8), which encodes a protein that is a member of the ATP-binding cassette transporters that promotes biliary excretion of sterols \[[@B44]\]. Carbofuran belongs to another class of insecticide, carbamates, that inhibits cholinesterase and has been shown to generate reactive oxygen species and induce lipid peroxidation \[[@B45]\]. Carbofuran interacted with *A4GALT* (alpha 1,4-galactosyltransferase) which is involved in the formation of a glycolipid that provides cellular energy \[[@B46]\].

Among the herbicides, EPTC, classified as a thiocarbamate, has been reported to disrupt the biosynthesis of lipid metabolism in plants \[[@B47]\]. EPTC interacted with ALOX15, another gene in the lipoxygenase family that is involved in the metabolism of arachidonic and linoleic acid. Petroleum oil, which contains a mixture of hydrocarbons and is also lipophilic, is unique in that it is used as a herbicide, but also as an additive to other pesticides, and so it may have a wide variability in use \[[@B48]\]. It interacted with variants in three genes: ALOX5 (arachidonate 5-lipoxygenase), which transforms essential fatty acids into leukotrienes \[[@B49]\]; LRP1 (low-density lipoprotein receptor related protein 1), which regulates a large endocytic receptor that functions in lipoprotein transport \[[@B50]\]; ACSL5 (acyl-CoA synthetase long-chain 5) which converts free long-chain fatty acid to fatty acyl-CoA esters, and thereby plays a key role in lipid biosynthesis and fatty acid degradation \[[@B51]\]. Atrazine, a triazine herbicide, reported to be an endocrine disruptor in animals, was also shown to affect the lipid profiles of liver and muscle in fish \[[@B52]\]. It interacted with two genes belonging to the low-density lipoprotein receptor family (LDLR and LRP1). The low-density lipoprotein receptor (LDLR) is involved in the regulation of cholesterol homeostasis by receptor-mediated endocytosis \[[@B53]\].

While there is biologic plausibility to the interactions we observed, the specific biological mechanisms underlying these interactions are unclear. None of the SNPs we identified in our analysis are known to be functional or have been identified in published GWAS findings for prostate cancer (<http://www.genome.gov/gwastudies/>) \[[@B54]\]; however, they may be in linkage disequilibrium with other functional variants. Research conducted on the role of lipid metabolism in prostate carcinogenesis suggests that the mechanisms are complex, involving an array of intermediate compounds that can be modified by other pathways as well as various genetic, anthropometric, dietary, and lifestyle factors \[[@B55]\]. It is also possible that mechanisms other than lipid metabolism might play a role in the interactions we observed since most of the genes we identified have multiple functions. For example, genes within the arachidonic acid family play an important role in immunity and inflammation \[[@B56]\]. Furthermore, considering the findings from previous analyses from the nested case-control study of prostate cancer within AHS, we are seeing some of the same pesticides, such as terbufos, fonofos, carbofuran, EPTC, and petroleum oil, interacting with SNPs in multiple genetic pathways, suggesting that the relationship between pesticides and prostate cancer may involve multiple biologic processes.

In this analysis, we examined SNPs with a minor allele frequency (MAF) \>10% because of limited power below this MAF threshold and restricted analyses to SNPs with a main effect association with prostate cancer at *P* \< 0.2 to focus on SNPs potentially more associated with prostate cancer. However, by doing this, we may have excluded important SNPs that modify risk. Interaction analyses were conducted using the dominant genetic model since the number of participants in the homozygous variant group was often small; however, this may have resulted in loss of statistical power if another genetic model was more appropriate. Although some of our findings may be false-positives, we adopted a two-stage interaction approach and utilized FDR to limit this possibility. In addition, we focused our interpretations on interactions with positive monotonic associations between pesticide use and prostate cancer in one genotype and no significant association in the other genotype, which have greater biological plausibility than qualitative interactions, but could have resulted in exclusions of potentially relevant interactions. Due to small sample size we were unable to evaluate interactions by prostate cancer stage or grade.

In conclusion, we observed several positive interactions between pesticide use and variants in lipid metabolism genes. These findings suggest that lipid metabolism may be involved in the associations between pesticides and prostate cancer; however, little is known about the biologic mechanisms underlying these interactions. Furthermore, since this is the first study to explore the interaction between specific pesticide use and variants of genes in the lipid metabolism pathway, our results require replication.

Supplementary Material {#supplementary-material-sec}
======================

###### 

Supplemental Table 1: shows the distribution of the study population by selected characteristics along with the chi-square *p*-value.

Supplemental Table 2: shows the association between intensity-weighted lifetime days of pesticide use and prostate cancer.

Supplemental Table 3: shows prostate cancer risk in relation to the 220 variants in 59 genes included in our interaction analysis. These variants had a Hardy Weinberg Equilibrium *p*-value\>0.001, a minor allele frequency \>=0.1, and a *p*-trend for the additive effect of each allele\<0.2.

Supplemental Table 4: shows the associations between intensity-weighted lifetime days of pesticide use and prostate cancer risk stratified by SNP genotype. These associations showed significant FDR interactions between pesticide use and SNPs, and increased prostate cancer risk in at least one genotype

###### 

Click here for additional data file.
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###### 

Prostate cancer risk in relation to lipid metabolism variants with FDR *P* trend \<0.05 (sorted by gene and FDR *P*  trend).

  ------------------------------------------------------------------------------------------------------------------------------------------------------
  Gene                                                                                           Minor allele                                    
  ---------------------------------------------------- ---- ------------- ----------------- ---- -------------- ------- --------------- -------- -------
  *ABCG5*\                                             2    rs1835815\    IVS10−1132C\>T\   T\   0.28\          1.22\   (1.07--1.39)\   0.004\   0.01\
  (ATP-binding cassette subfamily G member 5)               rs2278356\    Ex13−265T\>G\     C\   0.31\          1.22\   (1.07--1.40)\   0.003\   0.01\
                                                            rs4952683\    IVS12−44A\>G\     G\   0.19\          1.21\   (1.04--1.41)\   0.02\    0.04\
                                                            rs10205816\   IVS11−2527T\>C\   G\   0.26\          1.16\   (1.01--1.33)\   0.04\    0.04\
                                                            rs4148214\    IVS4+43T\>C\      T\   0.46\          0.87\   (0.77--0.99)\   0.03\    0.04\
                                                            rs6709904     IVS6+317A\>G      G    0.10           1.23    (1.02--1.49)    0.03     0.04

  *ALOXE3*\                                            17   rs6503086     −15319C\>A        G    0.44           0.83    (0.73--0.94)    0.003    0.02
  (epidermis-type lipoxygenase 3)                                                                                                                

  *AMACR*\                                             5    rs299602\     IVS4−1798C\>T\    A\   0.31\          1.17\   (1.03--1.34)\   0.02\    0.04\
  (alpha-methylacyl-CoA racemase)                           rs6863657     IVS4+4012C\>T     A    0.11           0.77    (0.62--0.96)    0.02     0.04

  *FOXA3*\                                             19   rs11669442    IVS1−776T\>C      C    0.31           1.18    (1.03--1.35)    0.01     0.04
  (hepatocyte nuclear factor 3-gamma)                                                                                                            

  *LRP2*\                                              2    rs10490131\   IVS46−765T\>C\    G\   0.13\          1.24\   (1.05--1.47)\   0.01\    0.04\
  (low-density lipoprotein-related protein 2)               rs2239595\    IVS30+70C\>T\     A\   0.11\          1.33\   (1.11--1.61)\   0.002\   0.04\
                                                            rs2247506\    IVS4+23A\>G\      C\   0.19\          1.21\   (1.04--1.41)\   0.01\    0.04\
                                                            rs2268365\    IVS27−372A\>G\    C\   0.11\          1.27\   (1.05--1.53)\   0.01\    0.04\
                                                            rs2268372\    IVS38−824A\>T\    A\   0.18\          1.22\   (1.04--1.42)\   0.01\    0.04\
                                                            rs2673164     IVS4−2306G\>A     C    0.28           0.83    (0.72--0.95)    0.01     0.04

  *PPARA*\                                             22   rs4253655\    IVS3+1780G\>A\    A\   0.15\          1.24\   (1.05--1.46)\   0.01\    0.02\
  (peroxisome proliferator-activated receptor alpha)        rs6007662     IVS10+2685A\>G    G    0.25           1.20    (1.04--1.38)    0.01     0.02

  *TBXAS1*\                                            7    rs2284212     IVS9−11575G\>A    A    0.28           1.22    (1.07--1.40)    0.004    0.04
  (thromboxane A synthase 1)                                                                                                                     

  *UCP3*\                                              11   rs1726764     −13576A\>G        C    0.47           1.17    (1.04--1.33)    0.01     0.03
  (mitochondrial uncoupling protein 3)                                                                                                           
  ------------------------------------------------------------------------------------------------------------------------------------------------------

^1^Frequency of variant allele among controls.

^2^Risk estimate for effect per allele assuming log-additive model adjusting for age and state.

###### 

Associations between intensity-weighted lifetime days of pesticide use and prostate cancer risk by lipid metabolism variants where FDR *P* interaction \<0.2^1^.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Pesticide   Gene                              SNP          SNP region      Genotype   Nonexposed   Low exposed   High exposed   Exposure trend   *P* interaction^2^   FDR *P* interaction^1,2^                                                                                     
  ----------- --------------------------------- ------------ --------------- ---------- ------------ ------------- -------------- ---------------- -------------------- -------------------------- --------- ------- --------------- ------- ------- --------------- ------- ------- ------
              *ALOXE3*\                         rs3027208    IVS7+369G\>A    CC\        307/576\     REF\          102/195\       0.99\            (0.74--1.31)\        0.93\                      81/188\   0.81\   (0.60--1.10)\   0.18\   0.91\   (0.79--1.05)\   0.22\   0.001   0.08
              (epidermis-type lipoxygenase 3)                                CT+TT      99/227       REF           43/55          1.86             (1.16--2.99)         0.01                       50/60     2.00    (1.28--3.15)    0.00    1.45    (1.16--1.81)    0.001           

  Terbufos    *SEC14L2*\                        rs2072159    IVS2−93G\>A     GG\        201/457\     REF\          83/139\        1.38\            (0.99--1.92)\        0.05\                      82/132\   1.43\   (1.03--1.99)\   0.03\   1.21\   (1.03--1.42)\   0.02\   0.003   0.15
              (SEC14-like protein 2)                                         AG+AA      204/342      REF           61/108         0.97             (0.67--1.40)         0.88                       47/115    0.70    (0.48--1.03)    0.07    0.86    (0.71--1.03)    0.10            

              *ADIPOR1*\                        rsl2733285   IVS1−1748G\>A   CC\        183/421\     REF\          74/123\        1.39\            (0.98--1.96)\        0.07\                      80/131\   1.43\   (1.02--1.99)\   0.04\   1.21\   (1.03--1.43)\   0.02\   0.01    0.18
              (adiponectin receptor 1)                                       CT+TT      223/372      REF           70/126         0.96             (0.68--1.35)         0.80                       51/117    0.75    (0.52--1.10)    0.14    0.88    (0.74--1.05)    0.16            
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

^1^Accounts for 220 SNPs included in interaction analyses.

^2^Risk estimates adjusted for age and state.

###### 

Associations between intensity-weighted lifetime days of pesticide use and prostate cancer risk by lipid metabolism variants where FDR *P* interaction \<0.05^1^.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Pesticide                                              Gene                                               SNP             SNP region      Genotype   Non-exposed   Low exposed   High exposed    Exposure trend   *P* interaction^2^   FDR *P* interaction^1,2^                                                                                                                    
  ------------------------------------------------------ -------------------------------------------------- --------------- --------------- ---------- ------------- ------------- --------------- ---------------- -------------------- -------------------------- --------------- --------------- --------------- --------------- --------------- --------------- -------- ------- ------
  Insecticides                                                                                                                                                                                                                                                                                                                                                                       

                                                                                                                                                                                                                                                                                                                                                                                     

  Terbufos                                               *ALOXE3*\                                          rs3027208       IVS7+369G\>A    CC\        307/576\      REF\          102/195\        0.99\            (0.74--1.31)\        0.93\                      81/188\         0.81\           (0.60--1.10)\   0.18\           0.91\           (0.79--1.05)\   0.22\    0.001   0.01
                                                         (epidermis-type lip oxygenase 3)                                                   CT+TT      99/227        REF           43/55           1.86             (1.16--2.99)         0.01                       50/60           2.00            (1.28--3.15)    0.00            1.45            (1.16--1.81)    0.001            

  *SEC14L2*\                                             rs2072159                                          IVS2−93G\>A     GG\             201/457\   REF\          83/139\       1.38\           (0.99--1.92)\    0.05\                82/132\                    1.43\           (1.03--1.99)\   0.03\           1.21\           (1.03--1.42)\   0.02\           0.003    0.01    
  (SEC14-like protein 2)                                                                                                    AG+AA           204/342    REF           61/108        0.97            (0.67--1.40)     0.88                 47/115                     0.70            (0.48--1.03)    0.07            0.86            (0.71--1.03)    0.10                             

  *ADIPOR1*\                                             rs12733285                                         IVS1−1748G\>A   CC\             183/421\   REF\          74/123\       1.39\           (0.98--1.96)\    0.07\                80/131\                    1.43\           (1.02--1.99)\   0.04\           1.21\           (1.03--1.43)\   0.02\           0.01     0.02    
  (adiponectin receptor 1)                                                                                                  CT+TT           223/372    REF           70/126        0.96            (0.68--1.35)     0.80                 51/117                     0.75            (0.52--1.10)    0.14            0.88            (0.74--1.05)    0.16                             

                                                                                                                                                                                                                                                                                                                                                                                     

  Fonofos                                                *ABCG8*\                                           rs4953028       IVS10+205G\>A   GG\        141/345\      REF\          26/38\          1.73\            (0.99--3.00)\        0.05\                      36/46\          1.94\           (1.17--3.20)\   0.01\           1.43\           (1.12--1.82)\   0.004\   0.005   0.02
                                                         (ATP-binding cassette subfamily G member 8)                                        AG+AA      368/644       REF           59/120          0.89             (0.63--1.25)         0.50                       56/106          0.95            (0.66--1.36)    0.77            0.96            (0.81--1.14)    0.63             

                                                                                                                                                                                                                                                                                                                                                                                     

  Carbofuran                                             *A4GALT*\                                          rs8136914       IVS1+4129T\>C   AA\        210/477\      REF\          69/128\         1.22\            (0.87--1.71)\        0.25\                      72/115\         1.43\           (1.02--2.00)\   0.04\           1.20\           (1.02--1.41)\   0.03\    0.02    0.03
                                                         (lactosylceramide 4-alpha-galactosyltransferase)                                   AG+GG      222/378       REF           54/93           1.01             (0.69--1.47)         0.96                       48/107          0.76            (0.52--1.12)    0.17            0.89            (0.75--1.07)    0.22             

                                                                                                                                                                                                                                                                                                                                                                                     

  *LDLR*\                                                rs8110695                                          IVS1−4369T\>A   TT\             285/509\   REF\          76/132\       1.04\           (0.75--1.43)\    0.82\                64/138\                    0.83\           (0.60--1.16)\   0.27\           0.93\           (0.80--1.09)\   0.36\           0.02     0.04    
  (low-density lipoprotein receptor)                                                                                        AT+AA           145/342    REF           47/92         1.17            (0.78--1.76)     0.44                 55/83                      1.58            (1.06--2.33)    0.02            1.24            (1.03--1.51)    0.02                             

                                                                                                                                                                                                                                                                                                                                                                                     

  Herbicides                                                                                                                                                                                                                                                                                                                                                                         

                                                                                                                                                                                                                                                                                                                                                                                     

  EPTC                                                   *ALOX15*\                                          rs916055        Ex14+241T\>C    AA\        242/433\      REF\          34/45\          1.38\            (0.85--2.23)\        0.19\                      18/58\          0.56\           (0.32--0.99)\   0.05\           0.85\           (0.67--1.09)\   0.19\    0.01    0.01
                                                         (arachidonate 15-lipoxygenase)                                                     AG+GG      274/592       REF           45/70           1.47             (0.98--2.22)         0.06                       42/58           1.63            (1.06--2.50)    0.02            1.31            (1.07--1.60)    0.01             

                                                                                                                                                                                                                                                                                                                                                                                     

  Petroleum iil/distillates                              *ALOX5*\                                           rs7099684       IVS12−61T\>C    TT\        281/602\      REF\          33/63\          1.19\            (0.76--1.86)\        0.45\                      43/60\          1.56\           (1.03--2.38)\   0.04\           1.24\           (1.02--1.51)\   0.03\    0.02    0.02
                                                         (arachidonate 5-lipoxygenase)                                                      AT+AA      200/346       REF           19/36           0.91             (0.51--1.63)         0.76                       14/41           0.60            (0.32--1.13)    0.12            0.80            (0.60--1.07)    0.13             

  *LRP1*\                                                rs1800159                                          IVS62+86A\>G    GG\             229/477\   REF\          18/51\        0.74\           (0.42--1.31)\    0.31\                20/58\                     0.72\           (0.42--1.23)\   0.23\           0.83\           (0.65--1.07)\   0.15\           0.01     0.03    
  (low-density lipoprotein receptor-related protein 1)                                                                      AG+AA           258/484    REF           34/52         1.26            (0.80--2.00)     0.32                 41/45                      1.76            (1.12--2.77)    0.01            1.32            (1.07--1.63)    0.01                             

  rs7956957                                              IVS78−51C\>G                                       GG\             209/417\        REF\       14/44\        0.66\         (0.35--1.23)\   0.19\            17/46\               0.75\                      (0.42--1.34)\   0.33\           0.83\           (0.63--1.09)\   0.17\           0.02            0.03             
                                                                                                            CG+CC           279/547         REF        38/59         1.32          (0.85--2.03)    0.22             44/57                1.57                       (1.03--2.40)    0.04            1.26            (1.04--1.54)    0.02                                             

  rs6581128                                              IVS42−916C\>A                                      CC\             227/452\        REF\       21/49\        0.87\         (0.51--1.49)\   0.61\            18/51\               0.70\                      (0.40--1.23)\   0.22\           0.84\           (0.65--1.09)\   0.20\           0.02            0.03             
                                                                                                            AC+AA           261/509         REF        31/54         1.17          (0.73--1.87)    0.52             43/50                1.73                       (1.12--2.68)    0.01            1.29            (1.05--1.59)    0.01                                             

  rs7978567                                              IVS67−220C\>T                                      CC\             219/437\        REF\       16/48\        0.69\         (0.38--1.25)\   0.22\            20/49\               0.83\                      (0.48--1.43)\   0.49\           0.87\           (0.67--1.13)\   0.29\           0.03            0.04             
                                                                                                            CT+TT           268/527         REF        36/55         1.34          (0.86--2.10)    0.20             41/54                1.56                       (1.01--2.41)    0.05            1.26            (1.03--1.55)    0.02                                             

  *ACSL5*\                                               rs12098576                                         IVS6−530C\>A    GG\             379/715\   REF\          35/71\        0.96\           (0.63--1.47)\    0.86\                40/84\                     0.93\           (0.62--1.39)\   0.72\           0.96\           (0.80--1.16)\   0.70\           0.01     0.04    
  (acyl-CoA synthetase long hain)                                                                                           GT+TT           109/249    REF           17/32         1.20            (0.64--2.26)     0.57                 21/19                      2.54            (1.31--4.92)    0.01            1.51            (1.11--2.05)    0.01                             

                                                         rs876873                                           IVS6−530C\>A    TT\             369/691\   REF\          32/69\        0.90\           (0.58--1.39)\    0.62\                38/80\                     0.93\           (0.61--1.39)\   0.71\           0.95\           (0.79--1.15)\   0.61\           0.01     0.04    
                                                                                                                            CT+CC           119/269    REF           20/34         1.33            (0.73--2.41)     0.35                 23/21                      2.46            (1.31--4.63)    0.01            1.52            (1.14--2.04)    0.005                            

                                                                                                                                                                                                                                                                                                                                                                                     

  Glyphosate                                             *ALOX5AP*\                                         rs9579645       IVS1+694A\>C    AA\        151/241\      REF\          227/433\        0.84\            (0.64--1.09)\        0.18\                      200/410\        0.78\           (0.59--1.02)\   0.07\           0.89\           (0.77--1.02)\   0.08\    0.004   0.02
                                                         (arachidonate 5-lipoxygenase-activating protein)                                   AC+CC      31/91         REF           48/109          1.25             (0.73--2.16)         0.42                       71/120          1.74            (1.03--2.93)    0.04            1.33            (1.03--1.72)    0.03             

                                                                                                                                                                                                                                                                                                                                                                                     

  Atrazine                                               *LDLR*\                                            rs8110695       IVS1−4369T\>A   TT\        128/223\      REF\          181/307\        1.04\            (0.78--1.40)\        0.79\                      154/315\        0.86\           (0.64--1.16)\   0.33\           0.92\           (0.79--1.07)\   0.27\    0.02    0.03
                                                         (low-density lipoprotein receptor)                                                 AT+AA      60/150        REF           92/207          1.11             (0.75--1.66)         0.59                       117/199         1.49            (1.01--2.19)    0.04            1.23            (1.02--1.49)    0.03             

  *LRP1*\                                                rs1800159                                          IVS62+86A\>G    GG\             91/173\    REF\          117/261\      0.85\           (0.60--1.19)\    0.34\                108/273\                   0.74\           (0.52--1.05)\   0.09\           0.86\           (0.73--1.02)\   0.09\           0.01     0.04    
  (low-density lipoprotein receptor-related protein 1)                                                                      AG+AA           98/202     REF           156/254       1.32            (0.95--1.82)     0.10                 165/241                    1.46            (1.06--2.02)    0.02            1.20            (1.02--1.40)    0.02                             
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

^1^Accounts for the number of SNPs per gene.

^2^Risk estimates adjusted for age and state.

[^1]: Academic Editor: Lars Holmberg
